Tags : Concerto HealthAI

Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative

Tuba Khan April 11, 2019

Shots: Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML The companies will utilize ASCO’s CancerLinQ […]readmore

Tags : Concerto HealthAI

Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Concerto HealthAI

﻿Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative